Literature DB >> 30279843

Superior vena cava syndrome complicated with acute pulmonary thromboembolism in a patient with lung cancer.

Chye-Gen Chin1, Jong-Shiuan Yeh1,2, Yung-Kuo Lin1,2, Weng-Chio Tam1,2.   

Abstract

Thrombosis involving the subclavian vein and superior vena cava is relatively common, especially in cancer patients. Edema of the arms and head is a well-known clinical consequence of this thrombosis. The intrinsic risk of pulmonary embolism has not been reported previously. Herein, we describe the case of a 63-year-old male patient with extensive stage small cell lung cancer who developed superior vena cava syndrome. Pulmonary thromboembolism was complicated after receiving systemic chemotherapy and localized radiotherapy. <Learning objective: Superior vena cava (SVC) syndrome may pose a significant risk factor of pulmonary thromboembolism. Although SVC syndrome and pulmonary thromboembolism may have similar comorbidities, pulmonary thromboembolism might occur after treatment of SVC syndrome. Possible mechanisms may be related to tumor debris and hypercoagulable central vein thrombosis. Physicians must be vigilant with patients whom have dyspnea after treatment of SVC syndrome. Computed tomography angiography may help make an early diagnosis if clinical suspicion is made.>.

Entities:  

Keywords:  Lung cancer; Pulmonary embolism; Superior vena cava syndrome

Year:  2017        PMID: 30279843      PMCID: PMC6149638          DOI: 10.1016/j.jccase.2017.08.004

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  9 in total

1.  OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism.

Authors:  A Young; J Phillips; H Hancocks; C Hill; N Joshi; A Marshall; J Grumett; J A Dunn; A Lokare; O Chapman
Journal:  Thromb Res       Date:  2016-04-08       Impact factor: 3.944

Review 2.  Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Gary H Lyman; Kari Bohlke; Anna Falanga
Journal:  J Oncol Pract       Date:  2015-04-14       Impact factor: 3.840

Review 3.  Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.

Authors:  Maria Cristina Vedovati; Federico Germini; Giancarlo Agnelli; Cecilia Becattini
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

4.  Thromboembolic disease involving the superior vena cava and brachiocephalic veins.

Authors:  Todd R Otten; Paul D Stein; Kalpesh C Patel; Syed Mustafa; Allen Silbergleit
Journal:  Chest       Date:  2003-03       Impact factor: 9.410

5.  Syncope as an emergency department presentation of pulmonary embolism.

Authors:  T R Wolfe; T L Allen
Journal:  J Emerg Med       Date:  1998 Jan-Feb       Impact factor: 1.484

Review 6.  Pulmonary embolism presenting as syncope: case report and review of the literature.

Authors:  P Koutkia; T J Wachtel
Journal:  Heart Lung       Date:  1999 Sep-Oct       Impact factor: 2.210

7.  Thrombogenic role of cells undergoing apoptosis.

Authors:  J Wang; I Weiss; K Svoboda; H C Kwaan
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

Review 8.  Intracardiac thrombus, superior vena cava syndrome, and pulmonary embolism in a patient with Behçet's disease: a case report and literature review.

Authors:  Takashi Kajiya; Ryuichiro Anan; Masahiro Kameko; Naoko Mizukami; Shinichi Minagoe; Shuichi Hamasaki; Ikuro Maruyama; Ryuzo Sakata; Chuwa Tei
Journal:  Heart Vessels       Date:  2007-07-20       Impact factor: 2.037

9.  Investigation of proposed mechanisms of chemotherapy-induced venous thromboembolism: endothelial cell activation and procoagulant release due to apoptosis.

Authors:  Cliona C Kirwan; C N McCollum; G McDowell; G J Byrne
Journal:  Clin Appl Thromb Hemost       Date:  2015-03-05       Impact factor: 2.389

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.